Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 7.01 (Regulation FD Disclosure). Phase 3 FoCus analyses indicate ALXN1840 delivered greater neurologic and global clinical benefit versus standard of care.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 3 FoCus analyses indicate ALXN1840 delivered greater neurologic and global clinical benefit versus standard of care
- Results target Wilson disease, supporting ALXN1840’s potential differentiation in a late-stage program
- Data presentation at the 12th EAN Congress June 27–30, 2026 increases visibility with neurology specialists
- Press release and poster presentation furnished as Exhibits 99.1 and 99.2 for detailed efficacy analyses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.